Figure 8

The effects of co-targeting pathways on FN distribution in NB + 12 SMGs. Control SMGs (A) show a distinct and well-demarcated pattern of FN immunoreactivity at the BMZ (white arrow). B-F. mCMV-infected SMGs. In mCMV-infected SMGs (B), FN immunoreactivity is found surrounding abnormal stromal cells (white arrowheads) but is relatively absent at the epithelial BMZ (double white arrow). In GEF-treated, mCMV-infected SMGs treated with U0126 beginning on day 6 (C), FN immunostaining is primarily seen surrounding stromal cells (white arrowhead) and is mostly absent from BMZ (double white arrows); FN is sporadically seen in BMZ (white arrow). In U0126-treated, mCMV-infected SMGs treated with GEF beginning on day 6 (D), FN is immunolocalized both at the BMZ (white arrow) and surrounding abnormal stromal cells (white arrowheads) but is absent from the BMZ of a subset of epithelial islands (double white arrows). The addition of aciclovir treatment beginning day 6 to GEF-treated, mCMV-infected SMGs (E) or U0126-treated, mCMV-infected SMGs (F) results in a more normal staining pattern; FN immunostain is primarily seen at the BMZ (white arrow) in a pattern resembling that seen in controls (compare E, F to A). Bar: 38 μm.